Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 20/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | DRD1 | P21728 | 2/20 | 0.42 |
| ▸ | DRD4 | P21917 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 15/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 8/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5113393 | 1.00 | ADRB2 (0.42) | ADRB2DRD2DRD1DRD4DRD3 | |
| SCHEMBL5120429 | 0.99 | ADRB2 (0.42) | ADRB2DRD2DRD1DRD4DRD3 | |
| SCHEMBL5120422 | 0.99 | ADRB2 (0.42) | ADRB2DRD2DRD1DRD4DRD3 | |
| SCHEMBL4821310 | 0.89 | ADRB2 (0.40) | ADRB2DRD2DRD1DRD4DRD3 | |
| SCHEMBL5120389 | 0.88 | ADRB2 (0.48) | ADRB2DRD2DRD1DRD4DRD3 | |
| SCHEMBL5126915 | 0.84 | ADRB2 (0.40) | ADRB2DRD2DRD1DRD4DRD3 | |
| SCHEMBL5126921 | 0.81 | RAF1 (0.40) | ADRB2DRD2DRD1DRD4DRD3 | |
| SCHEMBL14837102 | 0.80 | ADRB2 (0.54) | ADRB2DRD2DRD1DRD4DRD3 | |
| SCHEMBL14837103 | 0.80 | ADRB2 (0.54) | ADRB2DRD2DRD1DRD4DRD3 | |
| SCHEMBL5127611 | 0.80 | ADRB2 (0.44) | ADRB2DRD2DRD1DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7402598-B2 | Arylethanolamine β2-adrenoreceptor agonist compounds | GLAXO GROUP LIMITED (GB) | 2008-07-22 | — | — | US | disclosed |
| US-20060111344-A1 | Arylethanolamine beta2-adrenoreceptor agonist compounds | GLAXO GROUP LIMITED (GB) | 2006-05-25 | — | — | US | disclosed |
| EP-1525180-A2 | ARYLETHANOLAMINE BETA2-ADRENORECEPTOR AGONIST COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-04-27 | — | — | EP | disclosed |
| WO-2004016578-A2 | ARYLETHANOLAMINE BETA2-ADRENORECEPTOR AGONIST COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111344-A1 | Arylethanolamine beta2-adrenoreceptor agonist compounds | ADRB2, ADRB1, ADRA2A | ADRB2 1/4885DRD2 329/4885DRD1 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.